[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: In this clinical study, the control group will receive only the standard care of the Ministry of Health protocol for COVID-19 patients for 1 month.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group (Pentoxifylline recipient + standard care): 100 patients with COVID-19 diagnosis will be included in the study according to the inclusion and exclusion criteria and will receive 400mg pentoxifylline tablet (produced by Amin pharmaceutical company in Iran) three times daily for 1 month along with the standard care of the Ministry of Health protocol.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 971, "treatment_name": "Pentoxifylline", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]